{"filings":[{"id":94671,"accession_number":"0001682852-26-000101","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Moderna amends bylaws for federal forum exclusivity; stockholders re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved bylaw amendment designating federal district courts as exclusive forum for Securities Act claims, effective immediately.","Stockholders re-elected Sandra Horning, M.D. and Abbas Hussain as Class II directors for three-year terms.","Say-on-pay advisory vote passed with 169M for, 90.8M against; company will hold annual advisory votes.","Ratification of Ernst & Young as independent auditor for FY 2026 approved with 298.8M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94670,"accession_number":"0001682852-26-000057","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q1 2026 revenue $389M, GAAP net loss $(1.3)B including $0.9B litigation charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $389M (+$281M YoY); ~80% from international; GAAP EPS $(3.40) vs $(2.52) YoY.","Net loss $(1.3)B includes $0.9B non-recurring litigation settlement charge; cash $7.5B.","Reaffirms up to 10% revenue growth in 2026; cost of sales guidance ~$1.8B including charge.","EU approved mNEXSPIKE and mCOMBRIAX (flu+COVID combo); Phase 3 initiated for intismeran in NSCLC.","R&D expenses down 24% YoY to $649M; SG&A down 18% to $173M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":389000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107226,"accession_number":"0001682852-26-000047","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Moderna settles all patent litigation with Arbutus/Genevant for $950M upfront, up to $1.3B contingent","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Moderna to pay $950M noncontingent lump sum by July 8, 2026 to resolve worldwide patent litigation over Spikevax and mRESVIA.","Additional $1.3B contingent payment due if Moderna loses appeal on Section 1498 government contractor defense at Federal Circuit.","Settlement includes fully paid-up, royalty-free license for Moderna's infectious disease vaccines using SM-102 LNP (Spikevax, mNEXSPIKE, mRESVIA, future pipeline).","Moderna may appeal Section 1498 issue; if partially successful, prorated amount of $1.3B may be due; if fully successful, no further payment.","Agreement provides mutual releases and dismissals of all pending claims in U.S. and international litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107225,"accession_number":"0001682852-26-000015","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q4 revenue $678M (-30% YoY); net loss $(826)M; FY2025 net loss $(2.8)B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $678M (-30% YoY); GAAP net loss $(826)M ($(2.11) EPS).","Full-year 2025 revenue $1.9B (-40% YoY); net loss $(2.8)B ($(7.26) EPS).","2026 guidance: up to 10% revenue growth; R&D ~$3.0B; year-end cash $5.5-6.0B.","U.S. FDA issued Refusal-to-File for seasonal flu vaccine (mRNA-1010); Moderna requested Type A meeting.","Norovirus Phase 3 fully enrolled; intismeran autogene Phase 2 bladder cancer fully enrolled; data readouts expected 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":1944000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107224,"accession_number":"0001682852-26-000012","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Moderna receives FDA Refusal-to-File for flu vaccine mRNA-1010; no impact on 2026 guidance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA CBER refused to review BLA for mRNA-1010 citing comparator choice, not safety/efficacy.","Moderna states RTF letter contradicts prior written feedback from pre-Phase 3 and pre-submission meetings.","Moderna has requested a Type A meeting with FDA to discuss path forward.","mRNA-1010 accepted for review in EU, Canada, Australia; earliest approval late 2026/early 2027.","Company reaffirms no change to 2026 financial guidance despite RTF."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107223,"accession_number":"0001682852-26-000007","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Moderna reports prelim 2025 rev ~$1.9B, cuts OpEx guidance, expects flu/COVID combo approvals in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 preliminary revenue ~$1.9B ($100M above midpoint); GAAP OpEx $5.0-5.2B (improved $200M).","Year-end cash ~$8.1B including $0.6B draw from new $1.5B Ares term loan facility.","2026 targets: up to 10% revenue growth, $4.9B GAAP OpEx; 2027 OpEx $4.2-4.6B, path to cash breakeven 2028.","Expects 2026 approvals of flu vaccine mRNA-1010 and flu/COVID combo mRNA-1083; multiple pivotal readouts in oncology/rare disease.","Closed $1.5B term loan from Ares; CEPI commits $54.3M for H5 pandemic flu vaccine Phase 3 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107222,"accession_number":"0001682852-26-000003","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moderna projects 2025 revenue $1.6-2.0B, targets up to 10% growth in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 revenue guidance of $1.6-2.0B; cash costs beat commitments by nearly $1B.","mNEXSPIKE captured ~24% of U.S. retail COVID shots and ~33% of 65+ segment.","Secured $1.5B five-year term loan; GAAP opex to fall below $5.5B in 2025 from $7.2B in 2024.","Cash cost target: ~$4.2B in 2026 and $3.5-3.9B in 2027; cash breakeven targeted in 2028.","Pipeline: Phase 3 flu efficacy positive; intismeran Phase 2b data and nine oncology readouts expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123559,"accession_number":"0001628280-25-053816","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Moderna enters $1.5B credit facility with Ares; $600M initial term loan, $900M delayed draw","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.5B facility: $600M initial term loan and $900M delayed draw tranche available through Nov 2027/2028.","Interest at Term SOFR + 5.50% or base rate + 4.50%; maturity date November 24, 2030.","Secured by all assets of Moderna; guaranteed by US, Canadian, UK, Swiss, and Australian subsidiaries.","Minimum liquidity covenant of $500M ($750M if >$1B drawn); not tested if market cap >$5B.","Proceeds used for general corporate purposes; loan contingent on regulatory milestones for delayed draw portion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123558,"accession_number":"0001628280-25-053318","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moderna targets up to 10% revenue growth in 2026; closes $1.5B loan facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Targets up to 10% revenue growth in 2026; expanding seasonal vaccine franchise to up to six approved products by 2028.","Reducing 2026 and 2027 GAAP operating expenses by ~$0.5B each year on path to cash breakeven in 2028.","Closed a five-year $1.5B term loan facility from Ares Management Credit Funds; initial draw $0.6B.","Discontinues four pipeline programs: CMV, HSV, VZV, and GSD1a; advances nine oncology Phase 2/3 studies.","Updated 2025 year-end cash guidance to $7.1-$7.6B (from $6.5-$7.0B) due to loan draw."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123557,"accession_number":"0001628280-25-052055","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Moderna shareholders approve one-time stock option exchange program for non-Exec Committee employees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 (option exchange) passed: 231,049,158 votes for, 6,167,159 against, 250,409 abstain.","Proposal 2 (adjournment if needed) passed: 223,991,059 for, 13,198,386 against, 277,281 abstain.","No broker non-votes reported; special meeting held November 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123556,"accession_number":"0001682852-25-000073","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q3 net loss $200M, revenue $1.0B down 45% YoY; narrows 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $1.0B (down 45% YoY); net loss $(0.51)/share vs. EPS $0.03 in Q3 2024.","2025 revenue range narrowed to $1.6-2.0B; GAAP opex cut by $0.7B to $5.2-5.4B.","Year-end cash target raised by $0.5-1.0B to $6.5-7.0B; Q3-end cash $6.6B.","COVID vaccine sales $971M; RSV mRESVIA sales $2M; mNEXSPIKE launched in US.","Discontinues congenital CMV program after Phase 3 missed primary endpoint; norovirus study extends."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":1266000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140238,"accession_number":"0001682852-25-000041","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q2 net loss $0.8B, rev $142M (-41% YoY); cuts 2025 revenue guidance high end by $300M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $142M (-41% YoY); GAAP net loss $0.8B ($2.13 EPS loss).","2025 revenue guidance narrowed to $1.5-$2.2B (high end cut $300M due to UK delivery timing shift to 2026).","GAAP operating expenses expected $5.9-$6.1B, improved ~$400M; year-end cash ~$6B reiterated.","Announced three FDA approvals (mNEXSPIKE for high-risk adults, Spikevax for children, mRESVIA for 18-59) and positive Phase 3 flu vaccine efficacy data.","Restructuring: global workforce reduction of ~10%, targeting headcount under 5,000 by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":250000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157888,"accession_number":"0001682852-25-000036","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Moderna shareholders re-elect board, approve executive compensation, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class I directors re-elected: Bancel 245.5M for (5.2M against); Afeyan 218.6M for (32.1M against); Nader 195.4M for (55.2M against).","Advisory 'say-on-pay' passed with 192.3M for, 56.5M against, 43.3M broker non-votes.","Ratification of Ernst & Young as auditor for FY2025 approved with 290.7M for, 3.2M against.","Broker non-votes of 43.3M were present on all director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157887,"accession_number":"0001682852-25-000031","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q1 net loss $1.0B, revenue $108M; reiterates 2025 revenue guidance $1.5-2.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 revenue $108M (down 35% YoY); GAAP net loss $(1.0)B, EPS $(2.52).","Reiterates 2025 revenue guidance $1.5-2.5B; expects H1 revenue ~$0.2B due to seasonality.","Announces cost-cutting plan: reduce GAAP operating costs by $1.4-1.7B by 2027; new 2027 estimate $4.7-5.0B.","Pipeline milestones: next-gen COVID vaccine PDUFA May 31; RSV vaccine PDUFA June 12; flu/COVID combo approval targeted 2026.","Cash and investments $8.4B at March 31 (down from $9.5B at Dec 31); expects year-end ~$6B."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":108000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176268,"accession_number":"0001682852-25-000006","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q4 net loss $1.1B, EPS $(2.91); FY2024 revenue $3.2B falls 53%; guides 2025 rev $1.5-2.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $1.0B (-66% YoY); GAAP net loss $1.1B vs net income $217M in Q4 2023.","FY2024 revenue $3.2B (-53% YoY); GAAP net loss $3.6B; EPS $(9.28).","FY2024 cost of sales 47% of net product sales, including $238M non-cash charge for manufacturing agreement termination.","2025 revenue guided $1.5-2.5B; expects first-half 2025 revenue only ~$0.2B due to seasonality.","Filed three BLAs: next-gen COVID (PDUFA May 31), RSV for 18-59 (PDUFA June 12), flu/COVID combo."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":3236000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176267,"accession_number":"0001682852-25-000002","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Moderna: 2024 sales $3.0-3.1B; 2025 revenue guided $1.5-2.5B, down ~40%; CMV trial misses early efficacy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2024 product sales ~$3.0-3.1B (unaudited); cash & investments ~$9.5B. Full 2024 results due Feb 14, 2025.","2025 revenue guidance $1.5-2.5B (mostly H2); expects year-end cash ~$6.0B.","Accelerating cost cuts: $1B cash-cost reduction in 2025, additional $0.5B in 2026.","CMV vaccine Phase 3 DSMB: early efficacy not met; study continues blinded. Final data expected 2025.","Next-gen COVID BLA accepted (PDUFA May 31, 2025); RSV vaccine for high-risk adults filed; flu/COVID combo filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193159,"accession_number":"0001682852-24-000057","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q3 net income $13M, revenue $1.9B; reiterates FY product sales $3-3.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $13M ($0.03 EPS) vs net loss of $3.6B in Q3 2023; revenue $1.9B.","Net product sales $1.8B (+4% YoY); COVID-19 sales $1.8B, RSV sales $10M (below expectations).","FY 2024 product sales guidance reiterated at $3.0-3.5B; cost of sales guidance narrowed to 40-45%.","R&D lowered to $4.6-4.7B; capex raised to ~$1.2B including Norwood campus purchase ($0.4B).","Initiated Phase 3 trials for norovirus and influenza vaccines; expanded Executive Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":2270000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193158,"accession_number":"0001682852-24-000052","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Moderna appoints Abbas Hussain, ex-CEO of Vifor Pharma, to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hussain appointed effective Oct 2, 2024; board size fixed at nine directors.","He brings over 35 years of healthcare leadership, including former CEO of Vifor Pharma and Global President of GSK Pharmaceuticals & Vaccines.","Hussain will serve on the Audit Committee and receive standard non-employee director compensation plus initial and pro-rata annual equity grants.","No arrangements or relationships requiring disclosure under Item 404(a) of Regulation S-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209534,"accession_number":"0001682852-24-000049","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moderna outlines 10 product approvals by 2027; cuts R&D spend, issues 2025 revenue guidance $2.5-3.5B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects ten product approvals through 2027, including three respiratory vaccine submissions in 2024 (next-gen COVID, flu/COVID combo, RSV for high-risk adults).","Positive Phase 3 results for RSV vaccine in high-risk adults 18-59; sBLA filing planned in 2024 using Priority Review Voucher.","Cuts cumulative R&D spend for 2025-2028 by 20% to $16B; 2025 R&D guidance $4.2-4.5B; 2025 revenue guidance $2.5-3.5B.","Norovirus vaccine mRNA-1403 advances to Phase 3; INT melanoma Phase 3 substantially enrolled but FDA not supportive of accelerated approval.","Five pipeline programs discontinued; plans to break even on operating cash cost basis in 2028 with $6B revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209533,"accession_number":"0001682852-24-000043","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q2 net loss $1.3B, EPS $(3.33); cuts 2024 product sales forecast to $3.0-3.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $241M vs $344M YoY; net product sales $184M (-37%).","Revised FY2024 product sales guidance to $3.0-3.5B; cites low EU sales, deferrals, competitive US market.","RSV vaccine mRESVIA approved by FDA, shipping since July; EMA positive opinion.","Phase 3 data positive for combo flu+COVID and next-gen COVID vaccines; filings planned in 2024.","David Rubenstein joins Board Aug 5; Robert Langer and Stephen Berenson retire."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":408000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209532,"accession_number":"0001682852-24-000035","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Moderna appoints David Rubenstein to board; co-founders Langer and Berenson retire","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Rubenstein (Carlyle Co-Founder) joins Moderna board effective Aug 5, 2024, replacing Stephen Berenson on Audit Committee.","Robert Langer and Stephen Berenson will retire from board on Aug 5, 2024; both will provide advisory services through Nov 1, 2026.","Dr. Langer's and Mr. Berenson's resignations not due to any disagreement with Moderna's operations or policies.","Board size fixed at eight directors; search ongoing for replacement with scientific/innovation experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227618,"accession_number":"0001682852-24-000031","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Moderna shareholders approve special meeting right and officer exculpation amendments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved right for holders of at least 20% of shares to call a special meeting.","Shareholders approved officer exculpation amendment under new Delaware law provisions.","All three Class III directors (Langer, Nabel, Tallett) elected with strong support.","Say-on-pay and ratification of EY as auditor each passed with overwhelming majorities.","Amendments and restated certificate became effective upon filing with Delaware Secretary of State on May 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227617,"accession_number":"0001682852-24-000023","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q1 revenue $167M, net loss $1.2B; reaffirms FY 2024 sales ~$4B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $1.2B and diluted EPS of $(3.07) vs. $0.19 EPS a year ago.","Spikevax product sales fell 91% YoY to $167M; $100M U.S., $67M international.","Reaffirms 2024 product sales ~$4B; expects ~$0.3B net sales in H1 2024.","Cash and investments $12.2B at March 31, down from $13.3B at year-end 2023.","RSV vaccine launch targeted for fall 2024; flu vaccine filing expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":167000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}